A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers

Jian Zhang, Nong Yang, Dongmei Ji, Weina Shen, Wenhua Li, Rubing Han, Ning Wang, Haoxun Tao, Sonya C Chapman, Amanda K Sykes, Wanli Zhang, Xichun Hu, Jian Zhang, Nong Yang, Dongmei Ji, Weina Shen, Wenhua Li, Rubing Han, Ning Wang, Haoxun Tao, Sonya C Chapman, Amanda K Sykes, Wanli Zhang, Xichun Hu

Abstract

Background: Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, is approved in combination with endocrine therapy or as monotherapy for hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) advanced breast cancer outside of China.

Objective: To evaluate the safety, tolerability, and pharmacokinetic (PK) profile of abemaciclib in Chinese patients with advanced and/or metastatic cancers.

Patients and methods: A multicenter, open-label, phase I trial of abemaciclib in Chinese patients with advanced and/or metastatic cancers was conducted. Patients were randomized (1:1) to oral abemaciclib 150 or 200 mg every 12 h on a 28-day cycle. Safety analyses (primary outcome) included all patients receiving at least one dose of abemaciclib. PK and antitumor activity were also assessed.

Results: Of the 26 patients randomized, 25 received abemaciclib 150 mg (n = 12) or 200 mg (n = 13). All 25 patients reported ≥ 1 treatment-emergent adverse event (TEAE). The majority of TEAEs were Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or 2 in severity. The most frequent TEAEs of Grade ≥ 3 were neutropenia (32%) and thrombocytopenia (24%). Four patients (16%) discontinued treatment due to AEs. Abemaciclib exhibited slow absorption and clearance at single dose, with maximum concentrations achieved after around 6 h and an elimination half-life of approximately 24 h. No complete response was observed, two patients (8%) achieved partial response, with one confirmed responder, and the disease control rate was 68% (n = 17).

Conclusions: Abemaciclib was well tolerated and the safety and PK profiles in Chinese patients were comparable to those previously reported in non-Chinese populations. Preliminary antitumor activity was observed. CLINICALTRIALS.

Gov identifier: NCT02919696.

Conflict of interest statement

Rubing Han, Ning Wang, Haoxun Tao, Sonya C. Chapman, Amanda K. Sykes, and Wanli Zhang are employees and minor shareholders of Eli Lilly and Company. The remaining authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Abemaciclib mean plasma concentration-time following a single oral dose (a) and following twice-daily oral dosing (b). h hours, SD standard deviation

References

    1. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002;1602(1):73–87. doi: 10.1016/s0304-419x(02)00037-9.
    1. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1(3):222–231. doi: 10.1038/35106065.
    1. Altenburg JD, Farag SS. The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma. Expert Opin Investig Drugs. 2015;24(2):261–271. doi: 10.1517/13543784.2015.993753.
    1. Corona SP, Generali D. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Des Devel Ther. 2018;12:321–330. doi: 10.2147/DDDT.S137783.
    1. Lallena MJ, Boehnke K, Torres R, et al. Abstract 3101: In-vitro characterization of Abemaciclib pharmacology in ER+ breast cancer cell lines. Cancer Res. 2015;75(15 suppl):3101. doi: 10.1158/1538-7445.AM2015-3101.
    1. Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825–837. doi: 10.1007/s10637-014-0120-7.
    1. Torres-Guzman R, Calsina B, Hermoso A, Baquero C, Alvarez B, Amat J, et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. Oncotarget. 2017;8(41):69493–69507. doi: 10.18632/oncotarget.17778.
    1. Dickler MN, Tolaney SM, Rugo HS, Cortes J, Dieras V, Patt D, et al. MONARCH 1, a phase II study of Abemaciclib, a CDK4 and CDK6 inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(−) Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218–5224. doi: 10.1158/1078-0432.CCR-17-0754.
    1. Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, del Prado M, Lallena MJ, et al. Identification and characterization of LY2835219: A potent oral inhibitor of the cyclindependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity. Mol Cancer Ther. 2011;10(11_suppl):B233. doi: 10.1158/1535-7163.TARG-11-B233.
    1. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. J Clin Oncol. 2014;32(15_suppl):534. doi: 10.1200/jco.2014.32.15_suppl.534.
    1. Tolaney SM, Rosen LS, Beeram M, Goldman JW, Gandhi L, Tolcher AW, et al. Abstract P5–19-13: Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer. Cancer Res. 2015;75(9_suppl):P5–19–13. doi: 10.1158/1538-7445.SABCS14-P5-19-13.
    1. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6(7):740–753. doi: 10.1158/-16-0095.
    1. Goetz M, Toi M, Campone M, Paluch-Shimon S, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. doi: 10.1200/JCO.2017.75.6155.
    1. Sledge GW, Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. doi: 10.1200/JCO.2017.73.7585.
    1. Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, et al. Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemother Pharmacol. 2016;78(2):281–288. doi: 10.1007/s00280-016-3085-8.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655. doi: 10.1097/00000421-198212000-00014.
    1. Tolaney SM, Beeram M, Beck JT, Conlin AK, Dees EC, Dickler MN, Helsten TL, et al. A phase Ib study of abemaciclib with therapies for metastatic breast cancer. J Clin Oncol. 2015;33(15_suppl):522. doi: 10.1200/jco.2015.33.15_suppl.522.
    1. Goetz M, Beeram M, Beck T, Conlin A, Dees E, Dickler M, et al. Abstract P4-13-25: Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer. J Cancer Res. 2016;76(4_suppl):P4-13-25. doi: 10.1158/1538-7445.SABCS15-P4-13-25.
    1. Zhang QY, Sun T, Yin YM, et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020;12:1–14. doi: 10.1177/1758835920963925.
    1. Gervaso L, Montero AJ, Jia X, Khorana AA. Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors. J Thromb Haemost. 2020;18:162–168. doi: 10.1111/jth.14630.
    1. .
    1. O'Shaughnessy J, Chigutsa E, Kambhampati SRP, Sykes A, Frenzel M, Nanda S, Koustenis A, Smith I, Turner PK. Abemaciclib exposure-response relationship in patients with metastatic breast cancer in MONARCH 1. Cancer Res. 2017;77(4_suppl):P6-11-11. doi: 10.1158/1538-7445.SABCS16-P6-11-11.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir